67360-10-5Relevant academic research and scientific papers
One-pot synthesis of imidazolinium salts via the ring opening of tetrahydrofuran
Huang, Yong-Qing,Zhao, Yue,Wang, Peng,Okamura, Taka-Aki,Laforteza, Brian N.,Lu, Yi,Sun, Wei-Yin,Yu, Jin-Quan
, p. 12430 - 12433 (2017)
A new one-pot synthesis of C2-hydroxypropyl-substituted imidazolinium salts via the ring opening of tetrahydrofuran (THF) with N,N′-disubstituted diamines has been developed. Preliminary studies of the reaction mechanism suggest the CO2-promoted oxidative ring opening of THF followed by Hg(ii)-mediated oxidation of an imidazolidine intermediate. These novel C2-substituted imidazolinium salts have shown to be active catalysts for the aza-Diels-Alder reactions.
Flexible Analogues of Azaindole DYRK1A Inhibitors Elicit Cytotoxicity in Glioblastoma Cells
Zhou, Qingqing,Reekie, Tristan A.,Abbassi, Ramzi H.,Venkata, Dinesh Indurthi,Font, Josep S.,Ryan, Renae M.,Rendina, Louis M.,Munoz, Lenka,Kassiou, Michael
, p. 789 - 797 (2018/09/11)
DYRK1A is a novel target for epidermal growth factor receptor (EGFR)-dependent glioblastoma and it represents a promising strategy for cancer therapy. DYRK1A inhibition has been found to promote EGFR degradation in glioblastoma cells by triggering endocyt
Synthesis and biological evaluation of novel substituted-imidazolidine derivatives
Husain, Asif,Bhutani, Rubina,Kumar, Deepak,Shin, Dong-Soo
, p. 227 - 233 (2013/07/26)
A series of newer substituted-imidazolidine derivatives 3a-k were synthesized and assayed in vivo to investigate their anti-inflammatory, analgesic and antiulcer activity. The results of biological evaluation revealed that the three compounds, 4-[1,3-bis(4-hydroxy-3-methoxybenzyl)-2- imidazolidinyl]phenyldiethylamine (3g), 4-[1,3-bis(3-Ethoxy-4-hydroxybenzyl)-2- imidazolidinyl] phenyldiethylamine (3h) and 4-(1,3-bis(benzo[d][1,3]dioxol-5- ylmethyl)-4-methylimidazolidin-2-yl)-N,N-diethylbenzenamine (3j) were good in their anti-inflammatory and analgesic actions. Additionally these derivatives showed superior GI safety profile as compared to that of the standard drug in terms of low severity index. The results are statistically treated for its significance.
FBXO3 INHIBITORS
-
, (2014/01/08)
The present application discloses benzathine and related compounds and their use as FBXO-3 inhibitors.
